Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8745) 8745
Newsletter (212) 212
Newspaper Article (107) 107
Book Chapter (85) 85
Publication (6) 6
Magazine Article (5) 5
Trade Publication Article (4) 4
Dissertation (3) 3
Book / eBook (1) 1
Government Document (1) 1
Reference (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (7505) 7505
life sciences & biomedicine (6754) 6754
humans (5576) 5576
animals (4631) 4631
vascular endothelial growth factor (3968) 3968
angiogenesis (3032) 3032
vascular endothelial growth factor receptor-2 - metabolism (2675) 2675
mice (2510) 2510
female (2502) 2502
male (2391) 2391
oncology (1943) 1943
biological and medical sciences (1827) 1827
vascular endothelial growth factor a - metabolism (1736) 1736
medical sciences (1526) 1526
cell biology (1441) 1441
research (1273) 1273
vascular endothelial growth factor receptor-2 - genetics (1219) 1219
tumors (1189) 1189
endothelium (1141) 1141
cells, cultured (1126) 1126
signal transduction (1119) 1119
cancer (1097) 1097
middle aged (1081) 1081
cardiovascular system & cardiology (1035) 1035
proteins (968) 968
adult (945) 945
endothelial cells (939) 939
vegf (894) 894
analysis (887) 887
aged (879) 879
endothelial cells - metabolism (864) 864
gene expression (863) 863
vascular endothelial growth factor a - genetics (842) 842
rats (838) 838
biochemistry & molecular biology (814) 814
research article (786) 786
medicine (780) 780
neovascularization (775) 775
kinases (772) 772
rodents (767) 767
health aspects (766) 766
physiological aspects (764) 764
cell line, tumor (758) 758
care and treatment (757) 757
immunohistochemistry (746) 746
peripheral vascular disease (736) 736
science & technology - other topics (726) 726
mice, inbred c57bl (721) 721
cell proliferation (713) 713
multidisciplinary sciences (704) 704
apoptosis (676) 676
disease models, animal (653) 653
phosphorylation (651) 651
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (651) 651
hematology (649) 649
cardiovascular system (640) 640
medicine, research & experimental (640) 640
research & experimental medicine (640) 640
physiology (621) 621
abridged index medicus (601) 601
fundamental and applied biological sciences. psychology (595) 595
metastasis (571) 571
angiogenesis inhibitors - pharmacology (569) 569
medicine & public health (563) 563
cell proliferation - drug effects (552) 552
science (546) 546
cardiac & cardiovascular systems (540) 540
neovascularization, pathologic - metabolism (537) 537
biology (528) 528
genetic aspects (521) 521
inflammation (512) 512
signal transduction - drug effects (510) 510
endothelial cells - cytology (507) 507
neovascularization, physiologic (499) 499
neovascularization, pathologic - drug therapy (491) 491
studies (488) 488
vascular endothelial growth factor receptor-1 - metabolism (487) 487
stem cells (483) 483
growth factors (476) 476
review (472) 472
angiogenesis inhibitors - therapeutic use (471) 471
development and progression (471) 471
endothelium, vascular - metabolism (465) 465
pharmacology & pharmacy (465) 465
hypoxia (461) 461
endothelial cells - drug effects (460) 460
antineoplastic agents (454) 454
neovascularization, physiologic - drug effects (444) 444
chemotherapy (443) 443
mice, nude (437) 437
endothelium, vascular - cytology (434) 434
risk factors (430) 430
neovascularization, pathologic - pathology (416) 416
time factors (414) 414
rats, sprague-dawley (406) 406
cell line (404) 404
atherosclerosis (399) 399
cancer therapies (398) 398
immunology (394) 394
cell movement - drug effects (390) 390
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9139) 9139
Chinese (49) 49
Japanese (25) 25
German (10) 10
Russian (9) 9
Portuguese (6) 6
Polish (5) 5
Norwegian (4) 4
French (3) 3
Spanish (2) 2
Ukrainian (2) 2
Korean (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth
by Ebos, John M. L and Lee, Christina R and Bogdanovic, Elena and Alami, Jennifer and Van Slyke, Paul and Francia, Giulio and Xu, Ping and Mutsaers, Anthony J and Dumont, Daniel J and Kerbel, Robert S
Cancer research (Chicago, Ill.), ISSN 0008-5472, 01/2008, Volume 68, Issue 2, pp. 521 - 529
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Neoplasm Transplantation | Prostatic Neoplasms - metabolism | Adenocarcinoma - pathology | Adenoviridae | Cell Proliferation | Humans | Male | Transplantation, Heterologous | Mammary Neoplasms, Experimental - metabolism | Vascular Endothelial Growth Factor A - genetics | Mammary Neoplasms, Experimental - genetics | Adenocarcinoma - metabolism | Prostatic Neoplasms - genetics | Mammary Neoplasms, Experimental - pathology | Female | Tumor Burden - genetics | Adenocarcinoma - genetics | Tumor Cells, Cultured | Prostatic Neoplasms - pathology | Transduction, Genetic | Mice, Inbred C57BL | Solubility | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Mice, Transgenic | Biomarkers, Tumor - blood | HT29 Cells | Animals | Mice | Mice, Inbred BALB C | Vascular Endothelial Growth Factor A - physiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
by Wedge, Stephen R and Kendrew, Jane and Hennequin, Laurent F and Valentine, Paula J and Barry, Simon T and Brave, Sandra R and Smith, Neil R and James, Neil H and Dukes, Michael and Curwen, Jon O and Chester, Rosemary and Jackson, Janet A and Boffey, Sarah J and Kilburn, Lyndsey L and Barnett, Sharon and Richmond, Graham H.P and Wadsworth, Peter F and Walker, Mike and Bigley, Alison L and Taylor, Sian T and Cooper, Lee and Beck, Sarah and Jürgensmeier, Juliane M and Ogilvie, Donald J
Cancer research (Chicago, Ill.), ISSN 0008-5472, 05/2005, Volume 65, Issue 10, pp. 4389 - 4400
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Corpus Luteum - drug effects | Corpus Luteum - growth & development | Humans | Quinazolines - pharmacokinetics | Biological Availability | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Extracellular Matrix Proteins | Female | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Bone Development - drug effects | Administration, Oral | Endothelial Cells - metabolism | Neoplasms - enzymology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Neoplasms - blood supply | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Myosin Heavy Chains | Nonmuscle Myosin Type IIB | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Neoplasms - pathology | Quinazolines - pharmacology | Endothelial Cells - enzymology | Proteins - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors | Endothelial Cells - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth
by Dridi, Sami and Hirashima, Masanori and Albuquerque, Romulo J C and Cho, Won Gil and Kleinman, Mark E and Capoor, Seema and Baffi, Judit Z and Peterson, Martha L and Kaneko, Hiroki and Amano, Shiro and Chappell, Joe and Wilting, Jörg and Ambati, Jayakrishna and Takeda, Atsunobu and Yamada, Kiyoshi and Mizuki, Nobuhisa and Weich, Herbert A and Green, Martha G and Ambati, Balamurali K and Alexander, Jonathan S and Usui, Tomohiko and Brekken, Rolf A and Yamagami, Satoru and Hayashi, Takahiko
Nature medicine, ISSN 1078-8956, 09/2009, Volume 15, Issue 9, pp. 1023 - 1030
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Animals, Newborn | Vascular Endothelial Growth Factor C - physiology | Alternative Splicing | Lymphatic Vessels - physiology | Humans | Mice, Inbred C57BL | Vascular Endothelial Growth Factor Receptor-2 - deficiency | DNA, Complementary - genetics | Lymphangiogenesis - physiology | Molecular Sequence Data | Vascular Endothelial Growth Factor Receptor-2 - genetics | Cornea - metabolism | Animals | Cornea - blood supply | Vascular Endothelial Growth Factor C - antagonists & inhibitors | Mice, Mutant Strains | Base Sequence | Mice | Mice, Inbred BALB C | Vascular Endothelial Growth Factor Receptor-2 - physiology | Lymphangiogenesis - genetics | Cornea - growth & development | Physiological aspects | Vascular endothelial growth factor | Research | Proteins | Signal transduction | Cell growth | Lymphatic system | Molecular biology | Rodents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
by Chiorean, E.G and Hurwitz, H.I and Cohen, R.B and Schwartz, J.D and Dalal, R.P and Fox, F.E and Gao, L and Sweeney, C.J
Annals of oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1230 - 1237
phase I study | ramucirumab | VEGFR-2 | vascular endothelial growth factor | solid tumors | Phase I study | Ramucirumab | Solid tumors | Vascular endothelial growth factor | Life Sciences & Biomedicine | Oncology | Science & Technology | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Vascular Endothelial Growth Factor Receptor-2 - immunology | Angiogenesis Inhibitors - blood | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - administration & dosage | Neoplasms - blood | Adult | Female | Angiogenesis Inhibitors - adverse effects | Drug Administration Schedule | Vascular Endothelial Growth Factor A - blood | Antibodies, Monoclonal - pharmacokinetics | Neoplasms - enzymology | Vascular Endothelial Growth Factor Receptor-2 - blood | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Disease Progression | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Neoplasms - immunology | Aged | Neoplasms - pathology | Vascular Endothelial Growth Factor Receptor-1 - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text MicroRNA-16 and MicroRNA-424 Regulate Cell-Autonomous Angiogenic Functions in Endothelial Cells via Targeting Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1
by Chamorro-Jorganes, Aránzazu and Araldi, Elisa and Penalva, Luiz O.F and Sandhu, Devraj and Fernández-Hernando, Carlos and Suárez, Yajaira
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 11/2011, Volume 31, Issue 11, pp. 2595 - 2606
microRNAs | endothelium | angiogenesis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Blood vessels and receptors | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Atherosclerosis (general aspects, experimental research) | Biological and medical sciences | Medical sciences | Vertebrates: cardiovascular system | Blood and lymphatic vessels | Endothelium, Vascular - cytology | Cell Proliferation | Humans | Cells, Cultured | Mice, SCID | Receptor, Fibroblast Growth Factor, Type 1 - physiology | Cell Movement - physiology | Endothelium, Vascular - physiology | Neovascularization, Physiologic - physiology | Animals | Cattle | Signal Transduction - physiology | Mice | Vascular Endothelial Growth Factor Receptor-2 - physiology | 3' Untranslated Regions - physiology | MicroRNAs - physiology | Vascular Endothelial Growth Factor A - physiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Selective Imaging of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Atherosclerotic Lesions in Diabetic and Non-diabetic ApoE−/− Mice
by Tekabe, Yared and Tekabe, Yared and Johnson, Lynne L and Johnson, Lynne L and Rodriquez, Krissy and Rodriquez, Krissy and Li, Qing and Li, Qing and Backer, Marina and Backer, Marina and Backer, Joseph M and Backer, Joseph M
Molecular imaging and biology, ISSN 1536-1632, 2/2018, Volume 20, Issue 1, pp. 85 - 93
Molecular imaging | Vascular endothelial growth factor receptor (VEGFR) | Diabetes | Medicine & Public Health | Imaging / Radiology | Atherosclerosis | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Atherosclerosis - pathology | Diabetes Mellitus, Experimental - diagnosis | Apolipoproteins E - deficiency | Tomography, Emission-Computed, Single-Photon | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Atherosclerosis - complications | Male | Molecular Imaging - methods | Polyethylene Glycols - chemistry | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Apolipoproteins E - metabolism | Atherosclerosis - metabolism | Diabetes Mellitus, Experimental - blood | Tissue Distribution | Animals | Atherosclerosis - diagnosis | Diabetes Mellitus, Experimental - complications | Mice | Single-Chain Antibodies | Blood Glucose - metabolism | Diabetes Mellitus, Experimental - metabolism | Selectivity | Biology | Proteins | Angiogenesis | Receptors | Computed tomography | Apolipoprotein E | Polyethylene glycol | Imaging | Tomography | Aorta | Lesions | Vascular endothelial growth factor | Plaques | Photon emission | Medical imaging | Diabetes mellitus | Blood vessels | Single photon emission computed tomography | Mutants | Vascular endothelial growth factor receptors | Signaling | Computation | Arteriosclerosis | Coronary vessels | Tracers | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
by Jennifer L. Spratlin and Roger B. Cohen and Matthew Eadens and Lia Gore and D. Ross Camidge and Sami Diab and Stephen Leong and Cindy O'Bryant and Laura Q.M. Chow and Natalie J. Serkova and Neal J. Meropol and Nancy L. Lewis and E. Gabriela Chiorean and Floyd Fox and Hagop Youssoufian and Eric K. Rowinsky and S. Gail Eckhardt
Journal of clinical oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 780 - 787
Biological and medical sciences | Medical sciences | Tumors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Protein Kinase Inhibitors - adverse effects | Neovascularization, Pathologic - enzymology | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Vascular Endothelial Growth Factor A - blood | Antibodies, Monoclonal - pharmacokinetics | Neoplasms - enzymology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Neoplasms - blood supply | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Infusions, Intravenous | Vascular Endothelial Growth Factor Receptor-1 - blood | Index Medicus | Original Reports | Bone3 | Timg4 | Faze | To1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis
by Shibuya, Masabumi
Journal of biochemistry and molecular biology, ISSN 1225-8687, 09/2006, Volume 39, Issue 5, pp. 469 - 478
VEGFR2 | VEGFR1 | Agiogenesis | VEGF-E | Macrophages | Tyrosine kinase receptor | Vascular endothelial growth factor | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Signal Transduction | Atherosclerosis - physiopathology | Humans | Neovascularization, Pathologic | Vascular Endothelial Growth Factor Receptor-1 - physiology | Embryonic Development - physiology | Neoplasms - blood supply | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor Receptor-1 - chemistry | Pre-Eclampsia - physiopathology | Viral Proteins - metabolism | Vascular Endothelial Growth Factor Receptor-2 - genetics | Pregnancy | Vascular Endothelial Growth Factor Receptor-2 - chemistry | Animals | Neoplasm Metastasis - physiopathology | Female | Vascular Endothelial Growth Factor Receptor-2 - physiology | Neoplasms - physiopathology | Neovascularization, Physiologic | Inflammation - physiopathology | Vascular Endothelial Growth Factor Receptor-1 - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Myc‐dependent endothelial proliferation is controlled by phosphotyrosine 1212 in VEGF receptor‐2
by Testini, Chiara and Smith, Ross O and Jin, Yi and Martinsson, Pernilla and Sun, Ying and Hedlund, Marie and Sáinz‐Jaspeado, Miguel and Shibuya, Masabumi and Hellström, Mats and Claesson‐Welsh, Lena
EMBO reports, ISSN 1469-221X, 11/2019, Volume 20, Issue 11, pp. e47845 - n/a
GRB2 | PI3Kp85 | proliferation | angiogenesis | Nck | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Cell proliferation | Phosphorylation | Transcription | Gene regulation | Phosphotyrosine | AKT protein | Activation | Lethality | Myc protein | Kinases | Signal transduction | Pathways | Vascular endothelial growth factor | Growth factors | Tyrosine | Explants | Stability | Phenylalanine | Extracellular signal-regulated kinase | Blood vessels | Gene expression | Embryos | Endothelial cells | 1-Phosphatidylinositol 3-kinase | Grb2 protein | Signaling | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular Cancer
by Zhu, Andrew X and Finn, Richard S and Mulcahy, Mary and Gurtler, Jayne and Sun, Weijing and Schwartz, Jonathan D and Dalal, Rita P and Joshi, Adarsh and Hozak, Rebecca R and Xu, Yihuan and Ancukiewicz, Marek and Jain, Rakesh K and Nugent, Francis W and Duda, Dan G and Stuart, Keith
Clinical cancer research, ISSN 1078-0432, 12/2013, Volume 19, Issue 23, pp. 6614 - 6623
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Liver Neoplasms - mortality | Liver Neoplasms - blood | Pregnancy Proteins - blood | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Carcinoma, Hepatocellular - drug therapy | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - blood | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Biomarkers, Tumor - blood | Disease-Free Survival | Placenta Growth Factor | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights